Operational Impact of the Inflation Reduction Act (IRA) on Medicare Stakeholders
- Revenue Cycle
- Tuesday |
- 4/1/2025 |
- 4:30 PM –
- 5:30 PM
Operational Impact of the Inflation Reduction Act (IRA) on Medicare Stakeholders
The IRA provides Medicare beneficiaries with lower prescription drug costs and reduces overall drug spending by the federal government. For 2025, there is a positive change in the Medicare Part D benefit redesign for Medicare beneficiaries, which caps patient out-of-pocket drug costs at $2,000. In addition, the Medicare Prescription Payment Plan (MPPP) goes live in January 2025 as a new payment option for Medicare Part D beneficiaries, which will enable them to spread their out-of-pocket drug costs across the year.
The IRA provides Medicare beneficiaries with lower prescription drug costs and reduces overall drug spending by the federal government. For 2025, there is a positive change in the Medicare Part D benefit redesign for Medicare beneficiaries, which caps patient out-of-pocket drug costs at $2,000. In addition, the Medicare Prescription Payment Plan (MPPP) goes live in January 2025 as a new payment option for Medicare Part D beneficiaries, which will enable them to spread their out-of-pocket drug costs across the year.
Learning Objectives
Speaker(s)
Charles Collins
